BACKGROUND INFORMATION AND RATIONALE Infant respiratory distress is a leading cause of under-5 mortality worldwide, resulting in over one million infant deaths every year. Over 99% of these deaths occur in low to middle income countries For these vulnerable infants, noninvasive ventilation is preferred as it is associated with lower rates of chronic lung disease and ventilator-associated-pneumonia than invasive modes of ventilation. Widely used methods of noninvasive respiratory support for infants in respiratory distress include Nasal Continuous Positive Airway Pressure (NCPAP) and Nasal Intermittent Positive Pressure Ventilation (NIPPV). NCPAP consists of delivering a constant pressure, typically from 5 - 8 cm H2O, to recruit and stabilize the alveoli and improve ventilation and perfusion mismatch. NIPPV provides additional respiratory support with intermittent mandatory ventilation over the constant baseline pressure, e.g. 15 cm H2O over 5 cm H2O. The lower pressure is termed "P low" and the higher pressure is termed "P high". This additional respiratory support reduces the work of breathing3. In comparison with NCPAP, NIPPV has been shown to decrease the need for ventilation of preterm infants, decrease post-extubation failure and may further decrease the frequency of apneic episodes.
Bubble NCPAP is a simple, non-electric and easy to use means of delivering CPAP that has been successfully implemented across low and high resource settings 7,8. Unfortunately, until the present, there has not been an analogous simple, non-electric and easy to use means to deliver NIPPV. Conventional NIPPV equipment costs $10,000+, requires continuous electricity and requires many highly trained operators (physician, respiratory therapist, biomedical equipment technician), all of which serve as barriers to implementation in resource- constrained settings.
To address these barriers, a novel bubble NIPPV device, NeoVent, has been developed and shown to be both feasible and safe in a higher resourced nursery. With NeoVent, clinicians can independently set key parameters: upper level of pressure, lower level of pressure and rate (cycles/min). The technology is non-electric and visually intuitive to set up and operate. In the ASL 6000 infant lung simulator, NeoVent delivered comparable volumes and pressure waveforms as conventional ventilators. In sedated rabbits, NeoVent was able to achieve comparable ventilation, as demonstrated by arterial blood gas values, as a conventional ventilator13. In a first-in-human study of safety, NeoVent achieved a similar safety profile to bubble NCPAP 14. In a larger follow on study of safety, NeoVent again achieved a similar safety profile as bubble CPAP. Results have been published/presented in peer-reviewed forums including Pediatric Research, Respiratory Care, American Academy of Pediatrics, Indian Academy of Pediatrics, Canadian Society of Respiratory Therapists, Medicins Sans Frontieres and USAID/Gates Foundation's Grand Challenges in Global Health.
The investigators believe NIPPV using the Neovent is feasible for use by healthcare providers in lower resourced nurseries in Nepal and Nigeria; that NIPPV provided by Neovent will be as safe as breathing support providing by machine CPAP and newborns on Neovent will not have more nasal irritation or nose bleeds, more stomach problems, or air around their lungs than newborns on machine CPAP.
Primary Aim: Among infants (≤ 28 days) with respiratory distress settings, bubble NIPPV using the Neovent is feasible for use by healthcare providers in lower resourced nurseries in Nigeria and Nepal. This will test the hypothesis that at least 80% of healthcare providers' (clinicians/nurses) in lower resourced nurseries in Nigeria and Nepal can 1) set up, 2) operate and 3) troubleshoot bubble NIPPV using the Neovent and will be qualitatively assessed 3 months after introduction of the NIPPV in their NICU-based on survey/questionnaire/and demonstration.
Secondary Aims
* To demonstrate that health care providers in lower resourced nurseries in Nigeria and Nepal will be able evaluate for safety and correctly evaluate/stage nasal septal injury, nosebleeds, abdominal distention, clinically significant pneumothorax. This will test the hypothesis that healthcare providers in lower-resourced nurseries can correctly access for the primary safety concerns expected when using the Neovent.
* To demonstrate comparable rates of short-term complications (pneumothorax, nasal septal injury, nose bleeds, abdominal distention) between bubble NIPPV and those seen in previously with bubble CPAP. This will test the hypothesis that the side effects rates arse comparable in lower resourced nurseries to those seen both with bubble CPAP and with the Neovent in a higher resourced nurseries
Design: Over 6 months, 60 infants (≤28 days) and (≥30 weeks GA or ≥1000 grams if GA unknown) in mild to moderate respiratory distress in resource constrained referral hospitals in Nigeria and Nepal will be placed on bubble NIPPV with a Downes Score of 2-7. Health care providers (nurses together with physicians) ability to set up, operate and troubleshoot bubble NIPPV including monitoring for safety evaluating for nasal septal injury, abdominal distention and clinically significant pneumothorax will be qualitatively assessed.
Potential Impact: If bubble NIPPV is shown to be feasible and safe in resource constrained settings, this will justify further randomized controlled trials of efficacy.
Name and Description of Investigational Product or Intervention NeoVent delivers bubble Nasal Intermittent Positive Pressure Ventilation and is manufactured by Phoenix Medical Systems.
* 1 minute video describing device function: https://www.youtube.com/watch?v=cYZwbZK7lW4
* Product Description: https://www.phoenixmedicalsystems.com/infant-care/neovent Findings from Non-Clinical and Clinical Studies Pre-clinical studies In full-term and preterm neonatal manikins, bubble NIPPV reliably delivered alternating pressures consistent with standard NIPPV equipment9,10. In the IngMar ASL 5000 Test Lung simulator, delivered pressure waveforms and tidal volumes of bubble NIPPV were comparable with those of 2 conventional ventilators (Dräger Evita Infinity V500 and Hamilton G5) at the following pressure settings: 8/5, 12/5, and 15/5 cm H2O11,12. To simulate patients with pneumonia, transient tachypnea of the newborn and meconium aspiration syndrome, lung resistance was set at 100 cm H2O/L/s, and compliance set at 0.5, 1.0, and 2.0 mL/cm H2O15.
In anesthetized rabbits, bubble NIPPV reliably delivered two levels of airway pressure resulting in normalization of blood gases comparable to those achieved on a traditional ventilator13.
The delivery of comparable pressure waveforms and tidal volumes in lung simulators and normalization of arterial blood gas values in sedated animals suggests that bubble NIPPV provides treatment which may be comparable to traditional ventilator derived NIPPV. Thus, bubble NIPPV may provide clinicians in resource-limited settings with an additional, simple, non-electric treatment modality for the management of infant respiratory distress beyond bubble NCPAP alone.
Clinical studies Pilot data in a single center in Nepal In a cross-over cohort pilot in Nepal, 7 infants with moderate respiratory distress were randomized to 4 hours of treatment with bubble NCPAP vs bubble NIPPV followed by 4 hours of the alternate treatment. Vital signs, Downes' score (Retractions, Cyanosis, Respiratory Rate, Apnea, Expiratory Grunt) and O2 saturations were charted hourly. Survival and adverse events such as pneumothorax, nasal septal necrosis, necrotizing enterocolitis were recorded. All infants survived with similar median and interquartile values of vitals and Downes' scores, with no adverse events.
Safety in a single center in India At Paramitha Children's Hospital, a higher resourced nursery in Hyderabad, India, preterm (n=60) neonates with moderate respiratory distress were pragmatically allocated to bubble NCPAP (5-8 cm H2O) or bubble NIPPV (P high 8-10 cm H2O /P low 5-8 cm H2O) based on staff and equipment availability. Patient demographics on NCPAP and NIPPV were similar (mean +- SD; gestational age: 34.5 (1.4) vs. 34.6 (1.1) weeks; birth weight 2.2 (0.5) vs. 2.3 (0.4) kg; male: 67% vs. 67%) except for initial Respiratory Severity Score (RSS) which was 1.4 (0.4) on NCPAP vs. 2.4 (1.5) on NIPPV (p = .0008). Outcome measures included physiologic outcomes (hourly vital signs, Downes' score, FiO2), need for surfactant and need for intubation as well as complications including clinically relevant pneumothorax, septal necrosis, abdominal distention and other common complications of prematurity.
One patient in each arm developed minor nasal septal injury (grade 3 on NCPAP, grade 2 on NIPPV); no patients in either arm developed a clinically significant pneumothorax or abdominal distention. On NCPAP vs. NIPPV, 4 vs. 3 patients required a 1st dose of surfactant (excluding doses within the first two hours), and 1 vs. 0 patients required a second dose of surfactant. Two patients in the NCPAP arm required intubation in comparison with 4 patients in the NIPPV arm. There was a clinically and statistically significant improvement in FiO2 and Downes' score in NIPPV in comparison with NCPAP although patients on NIPPV did start with increased respiratory distress.
The similar rates of clinically significant nasal septal injury, pneumothorax and abdominal distention suggest that bubble NIPPV has a similar safety profile as bubble NCPAP for preterm infants in respiratory distress. Randomized controlled trials comparing the efficacy of bubble NCPAP and bubble NIPPV are warranted.
Given the demonstrated safety at one mid-resourced referral hospital, the investigators seek to study feasibility followed by efficacy in resource constrained hospitals.
Reference omitted but available upon request
